speakerspeaker

Speaker's Profile

Gregory Tobin

Biological Mimetics, Inc

Biography

Gregory Tobin, President and CEO of Biological Mimetics, Inc., has worked in the vaccine discovery field for over 30 years. He is the co-inventor of two novel vaccine platform technologies. The Immune Refocusing Technology (IRT) is used to identify epitopes that stimulate narrow, strain-restricted immunity and guide modifications of the antigen that enable the host immune system to mount more broadly protective responses to previously sub-dominant epitopes. BMI is currently developing IRT vaccines for universal influenza, human rhinovirus, and porcine circovirus-2 targets.

Today, Dr. Tobin will be discussing a second platform technology for irradiation-inactivated vaccines. The discussions will focus on the analysis of UltraIPV, an irradiation-inactivated Sabin-based vaccine and a presentation of its safety and economic advantages over traditional inactivated polio vaccines.

Quick Proposal

Get In Touch

Subscribe for updates:

Back to Top